| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Medical Oncology, Department of Internal Medicine, University Hospital, Zurich, Switzerland;
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213; and
Department of Otorhinolaryngology, University Schleswig, Luebeck, Germany
Naturally occurring CD4+CD25+ regulatory T (nTreg) cells are essential for maintaining T cell tolerance to self Ags. We show that discrimination of human Treg from effector CD4+CD25+ non-nTreg cells and their selective survival and proliferation can now be achieved using rapamycin (sirolimus). Human purified CD4+CD25high T cell subsets stimulated via TCR and CD28 or by IL-2 survived and expanded up to 40-fold in the presence of 1 nM rapamycin, while CD4+CD25low or CD4+CD25– T cells did not. The expanding pure populations of CD4+CD25high T cells were resistant to rapamycin-accelerated apoptosis. In contrast, proliferation of CD4+CD25– T cells was blocked by rapamycin, which induced their apoptosis. The rapamycin-expanded CD4+CD25high T cell populations retained a broad TCR repertoire and, like CD4+ CD25+ T cells freshly obtained from the peripheral circulation, constitutively expressed CD25, Foxp3, CD62L, glucocorticoid-induced TNFR family related protein, CTLA-4, and CCR-7. The rapamycin-expanded T cells suppressed proliferation and effector functions of allogeneic or autologous CD4+ and CD8+ T cells in vitro. They equally suppressed Ag-specific and nonspecific responses. Our studies have defined ex vivo conditions for robust expansion of pure populations of human nTreg cells with potent suppressive activity. It is expected that the availability of this otherwise rare T cell subset for further studies will help define the molecular basis of Treg-mediated suppression in humans.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported in part by a Swiss National Science Foundation special program, and a grant from the Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative, the Terry-Fox, Hanne-Liebermann, and Claudia-von-Schilling Foundation, and UBS Wealth Management. A.Z. was supported in part by the Emmy-Noether Program (Zi685-2/3) of the Deutsche Forschungsgemeinschaft. T.L.W. was supported in part by National Institutes of Health Grant PO-1 DE12321.
2 Address correspondence and reprint requests to Dr. Laura Strauss, University of Pittsburgh Cancer Institute, Research Pavilion at the Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh, PA 15213-1863; E-mail address: straussl{at}upmc.edu or Dr. Alfred Zippelius, Medical Oncology, Department of Internal Medicine, University Hospital, Raemistrasse 100, 8091, Zurich, Switzerland; E-mail address: Alfred.Zippelius{at}usz.ch
3 Abbreviations used in this paper: Treg, regulatory T; nTreg, naturally occurring CD4+CD25+ Treg; GITR, glucocorticoid-induced TNFR family related protein; TT, tetanus toxoid; ANX V, annexin V; LN, lymph node; MFI, mean fluorescence intensity; PI, propidium iodine.
This article has been cited by other articles:
|
|
 |
|
  M. Mandapathil, M. J. Szczepanski, M. Szajnik, J. Ren, D. E. Lenzner, E. K. Jackson, E. Gorelik, S. Lang, J. T. Johnson, and T. L. Whiteside Increased Ectonucleotidase Expression and Activity in Regulatory T Cells of Patients with Head and Neck Cancer Clin. Cancer Res., October 15, 2009; 15(20): 6348 - 6357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. U. Wieckowski, C. Visus, M. Szajnik, M. J. Szczepanski, W. J. Storkus, and T. L. Whiteside Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes J. Immunol., September 15, 2009; 183(6): 3720 - 3730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen, R. Das, R. Komorowski, A. Beres, M. J. Hessner, M. Mihara, and W. R. Drobyski Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease Blood, July 23, 2009; 114(4): 891 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-L. RIVAL-TRINGALI, S. EUVRARD, E. DECULLIER, A. CLAUDY, M. FAURE, and J. KANITAKIS Conversion from Calcineurin Inhibitors to Sirolimus Reduces Vascularization and Thickness of Post-transplant Cutaneous Squamous Cell Carcinomas Anticancer Res, June 1, 2009; 29(6): 1927 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Q. Tran, J. Andersson, D. Hardwick, L. Bebris, G. G. Illei, and E. M. Shevach Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures Blood, May 21, 2009; 113(21): 5125 - 5133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Szczepanski, M. Szajnik, M. Czystowska, M. Mandapathil, L. Strauss, A. Welsh, K. A. Foon, T. L. Whiteside, and M. Boyiadzis Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia Clin. Cancer Res., May 15, 2009; 15(10): 3325 - 3332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nagahama, Z. Fehervari, T. Oida, T. Yamaguchi, O. Ogawa, and S. Sakaguchi Differential control of allo-antigen-specific regulatory T cells and effector T cells by anti-CD4 and other agents in establishing transplantation tolerance Int. Immunol., April 1, 2009; 21(4): 379 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. O. Mouk, P. N. M. Mwinzi, C. L. Black, J. M. Carter, Z. W. Ng'ang'a, M. M. Gicheru, W. E. Secor, D. M. S. Karanja, and D. G. Colley Childhood Coinfections with Plasmodium falciparum and Schistosoma mansoni Result in Lower Percentages of Activated T Cells and T Regulatory Memory Cells than Schistosomiasis Only Am J Trop Med Hyg, March 1, 2009; 80(3): 475 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Strauss, C. Bergmann, and T. L. Whiteside Human Circulating CD4+CD25highFoxp3+ Regulatory T Cells Kill Autologous CD8+ but Not CD4+ Responder Cells by Fas-Mediated Apoptosis J. Immunol., February 1, 2009; 182(3): 1469 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Hippen, P. Harker-Murray, S. B. Porter, S. C. Merkel, A. Londer, D. K. Taylor, M. Bina, A. Panoskaltsis-Mortari, P. Rubinstein, N. Van Rooijen, et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells Blood, October 1, 2008; 112(7): 2847 - 2857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. N. Golovina, T. Mikheeva, M. M. Suhoski, N. A. Aqui, V. C. Tai, X. Shan, R. Liu, R. R. Balcarcel, N. Fisher, B. L. Levine, et al. CD28 Costimulation Is Essential for Human T Regulatory Expansion and Function J. Immunol., August 15, 2008; 181(4): 2855 - 2868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tao, L. Wang, K. M. Murphy, C. C. Fraser, and W. W. Hancock Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells J. Immunol., May 15, 2008; 180(10): 6649 - 6655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kang, S. J. Huddleston, J. M. Fraser, and A. Khoruts De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR J. Leukoc. Biol., May 1, 2008; 83(5): 1230 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Basu, T. Golovina, T. Mikheeva, C. H. June, and J. L. Riley Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin J. Immunol., May 1, 2008; 180(9): 5794 - 5798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Haxhinasto, D. Mathis, and C. Benoist The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells J. Exp. Med., March 17, 2008; 205(3): 565 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Strauss, C. Bergmann, M. J. Szczepanski, S. Lang, J. M. Kirkwood, and T. L. Whiteside Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression J. Immunol., March 1, 2008; 180(5): 2967 - 2980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Ward, A. M. Hall, L. S. Cairns, A. S. Leggat, S. J. Urbaniak, M. A. Vickers, and R. N. Barker Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia Blood, January 15, 2008; 111(2): 680 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zeiser, D. B. Leveson-Gower, E. A. Zambricki, N. Kambham, A. Beilhack, J. Loh, J.-Z. Hou, and R. S. Negrin Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells Blood, January 1, 2008; 111(1): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Strauss, C. Bergmann, W. Gooding, J. T. Johnson, and T. L. Whiteside The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., November 1, 2007; 13(21): 6301 - 6311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Watanabe, P. N. M. Mwinzi, C. L. Black, E. M. O. Muok, D. M. S. Karanja, W. E. Secor, and D. G. Colley T Regulatory Cell Levels Decrease in People Infected With Schistosoma mansoni on Effective Treatment Am J Trop Med Hyg, October 1, 2007; 77(4): 676 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bergmann, L. Strauss, R. Zeidler, S. Lang, and T. L. Whiteside Expansion of Human T Regulatory Type 1 Cells in the Microenvironment of Cyclooxygenase 2 Overexpressing Head and Neck Squamous Cell Carcinoma Cancer Res., September 15, 2007; 67(18): 8865 - 8873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson, and T. L. Whiteside A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-{beta}1 Mediates Suppression in the Tumor Microenvironment Clin. Cancer Res., August 1, 2007; 13(15): 4345 - 4354. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
